Gain Therapeutics Inc (GANX) Live Share Price, Invest From India

Gain Therapeutics Inc Stock Performance

as on April 18, 2026 at 6:59 am IST

Day's Low
Day's High
$2.06
Day's Price Range
$2.20
$2.13
3.29%
Downside
3.29%
Upside
52 Week's Low
52 Week's High
$1.41
52-Week Price Range
$4.34
$2.13
33.80%
Downside
103.76%
Upside

Gain Therapeutics Inc share price movements today

Previous Close: $2.05
Open: $2.06
Volume: 859.4K
Day's Low - High: $2.06 - $2.20
52 Week Low - High: $1.41 - $4.34

Gain Therapeutics Inc Historical Returns

1 Month Return: + 9.23 %
3 Month Return: + 17.68 %
1 Year Return: + 18.33 %
3 Year Return: -56.35 %
5 Year Return: -85.31 %

Gain Therapeutics Inc Stock Fundamentals & Key Indicators

Check Gain Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$87.1M

EPS (TTM)

-0.605

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-18.7M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-155.66%

Gain Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gain Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Gain Therapeutics Inc	BUY	$87.1M	-85.31%	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$41.3B	122.97%	133.47	8.45%
Vertex Pharmaceuticals Inc	BUY	$110.8B	101.1%	28.42	32.94%
BeiGene, Ltd.	NA	$37.2B	NA	131.65	5.37%
Regeneron Pharmaceuticals Inc	BUY	$78.9B	49.34%	17.98	31.41%

Stock Returns calculator for Gain Therapeutics Inc Stock including INR - Dollar returns

The Gain Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Gain Therapeutics Inc investment value today

Current value as on today

₹1,28,190

Returns

₹28,190

(+28.19%)

Returns from Gain Therapeutics Inc Stock

₹18,333 (+18.33%)

Dollar Impact

₹9,857 (+9.86%)

Analyst Recommendation on Gain Therapeutics Inc Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Gain Therapeutics Inc. Average target price of $7.6

Gain Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Gain Therapeutics Inc.

What analysts predicted

71.97%UPSIDE

Target Price

$7.6

Current Price

$2.13

Analyzed by

11 Analysts

Target

$7.60

Gain Therapeutics Inc target price $7.6, a slight upside of 71.97% compared to current price of $2.13. According to 11 analysts rating.

Gain Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Gain Therapeutics Inc Stock has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Time period: March 20, 2026 to April 19, 2026

Change:-3% versus previous 30 day period

Gain Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	0	-	-	-	0	-	-	-	-
Gross Profit	0	0	-2	-4	0	0	-2	-2	0	4
Operating Income	-4	-4	-4	-8	-4	-3	-4	-5	-4	-4
EBITDA	-4	-4	-4	-8	-4	-3	-4	-5	-4	-4
Interest Expense	-	0	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-4	-4	-3	-8	-4	-3	-4	-5	-4	-4
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income	-4	-4	-4	-8	-4	-3	-4	-5	-5	-4
Net Profit Margin	0.00%	-7290.08%	0.00%	0.00%	0.00%	-4581.88%	0.00%	0.00%	0.00%	0.00%

Gain Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	0	0	0	0	0	0	-	-
Gross Profit	0	0	0	-7	-8	0	0	0
Operating Income	-1	-2	-3	-13	-17	-22	-20	-18
EBITDA	-1	-2	-3	-13	-17	-22	-20	-18
Interest Expense	0	0	0	0	0	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-1	-2	-3	-13	-17	-22	-19	-19
Income Tax Expense	0	0	0	0	0	0	0	0
Net Income	-1	-2	-3	-13	-17	-22	-20	-20
Net Profit Margin	-5364.36%	-5310.88%	-12387.67%	-10371.70%	-13262.02%	-40354.33%	0.00%	0.00%

Gain Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-4	-4	-8	-4	-3	-4	-5	-5	-4
Operating Cash Flow	-5	-3	-5	-6	-3	-3	-5	-4	-4
Investing Cash Flow	3	3	2	0	0	-	-	-	-
Financing Cash Flow	9	0	10	0	2	2	2	7	16
Change in Cash	7	-1	6	-4	-1	-1	-2	2	12

Gain Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-2	-3	-13	-17	-22	-20	-20
Operating Cash Flow	-1	-3	-12	-14	-18	-18	-18
Investing Cash Flow	0	0	0	-14	10	4	-
Financing Cash Flow	1	10	41	0	12	13	28
Change in Cash	0	7	29	-29	4	-1	10

Global Institutional Holdings in Gain Therapeutics Inc

Funds	Holdings
Northern Trust Corp	0.21%
Susquehanna International Group, LLP	0.21%
Group One Trading, LP	0.13%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.	1.34%
Morgan Stanley - Brokerage Accounts	0.37%

See all

Insights on Gain Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, GANX stock has moved up by 18.3%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 40.2% return, outperforming this stock by 21.9%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 25.3% return, outperforming this stock by 82.4%

About Gain Therapeutics Inc

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Organisation	Gain Therapeutics Inc
Headquarters	4800 Montgomery Lane, Bethesda, MD, United States, 20814
Industry	Biotechnology
CEO	Mr. Gene Mack M.B.A.
E-voting on shares	Click here to vote

Key Management of Gain Therapeutics Inc

Name	Title
Dr. Khalid Islam Ph.D.	Chairman & Founder
Mr. Gene Mack M.B.A.	President, CEO & Director
Mr. Gianluca Fuggetta	Senior VP of Finance & Principal Financial Officer
Dr. Terenzio Ignoni Pharm.D.	Senior Vice President of Technical Operations
Dr. Joanne Taylor Ph.D.	Senior Vice President of Research
Dr. Jonas Hannestad M.D., Ph.D.	Chief Medical Officer

FAQs

What is Gain Therapeutics Inc share price today?

Gain Therapeutics Inc share price today is $2.13 as on April 18, 2026 at 1:29 am IST at the close of the market. Gain Therapeutics Inc share today touched a day high of $2.2 and a low of $2.06.

What is the 52 week high and 52 week low for Gain Therapeutics Inc share?

Gain Therapeutics Inc share touched a 52 week high of $4.34 on December 11, 2025 and a 52 week low of $1.41 on August 1, 2025. Gain Therapeutics Inc stock price today i.e. April 18, 2026 at 1:29 am IST is closed at $2.13,which is 50.92% down from its 52 week high and 51.06% up from its 52 week low.

What is Gain Therapeutics Inc's market capitalisation today?

Gain Therapeutics Inc market capitalisation is $0.00T as on April 18, 2026 at 1:29 am IST.

How to invest in Gain Therapeutics Inc Stock (GANX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Gain Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gain Therapeutics Inc Shares that will get you 0.7042 shares as per Gain Therapeutics Inc share price of $2.13 per share as on April 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy Gain Therapeutics Inc Stock (GANX) from India?

Indian investors can start investing in Gain Therapeutics Inc (GANX) shares with as little as ₹92.575 or $1 (as of April 19, 2026 at 12:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹925.75 in Gain Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on April 19, 2026 at 12:40 pm IST). Based on Gain Therapeutics Inc share’s latest price of $2.13 as on April 18, 2026 at 1:29 am IST, you will get 4.6948 shares of Gain Therapeutics Inc. Learn more about fractional shares .

What are the returns that Gain Therapeutics Inc has given to Indian investors in the last 5 years?

Gain Therapeutics Inc stock has given -85.31% share price returns and 24.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?